Drugs for Dementia
Overview
This report looks at prescribing trends in primary care for Drugs for Dementia at SICBl and ICB level with particular focus on low strength antipsychotics. Prescribing data is weighted with QoF registers.
If you have any queries about the content of the report please contact us at nuth.nyrdtc.rxsupp@nhs.net
Frequency
Quarterly
Data Period
October 2019 to September 2022
Drugs used in Diabetes
Overview
This report looks at prescribing trends in primary care for Drugs used in Diabetes at SICBl and ICB level with particular focus on insulins, anti-diabetic drugs and diagnostic & monitoring devices. Prescribing data is weighted with QoF registers, and also uses HES data to measure prescribing to outcomes.
If you have any queries about the content of the report please contact us at nuth.nyrdtc.rxsupp@nhs.net
Frequency
Quarterly
Data Period
October 2019 to September 2022
Formulary assessment – Glucagon (Ogluo)
Formulary assessment tools are templates to support local decision making. They list NICE guidance, MHRA safety advice, and other relevant high quality advice and guidelines relevant to making decisions for local formularies.
The templates are pre-populated with useful information to reduce duplication of effort, with space for the addition of local information as appropriate. The purpose of the document is to support consistent decision making by formulary groups and APCs.
This information is produced for use by NHS healthcare professionals and RDTC stakeholders.
Comparison of DPP-4 inhibitors (Gliptins)
Comparison documents are designed to support prescribers and medicines management teams to maximise health gains through the optimum use of medicines within a specific therapeutic area.
There are currently five dipeptidyl peptidase-4 (DPP-4) inhibitors (or gliptins) available in the UK for the management of type 2 diabetes mellitus. There are a number of differences between the DPP-4 inhibitors in terms of licensing, interactions, renal impairment dose adjustment, hepatic impairment dose adjustment, and cost. This comparison table allows prescribers and other healthcare professionals to easily compare the characteristics of these medicines.
Formulary assessment – metolazone (Xaqua)
Formulary assessment tools are templates to support local decision making. They list NICE guidance, MHRA safety advice, and other relevant high quality advice and guidelines relevant to making decisions for local formularies.
The templates are pre-populated with useful information to reduce duplication of effort, with space for the addition of local information as appropriate. The purpose of the document is to support consistent decision making by formulary groups and APCs.
This information is produced for use by NHS healthcare professionals and RDTC stakeholders.
Optimising the use of morphine 10mg/5mL oral solution in primary care (Update)
Overview
Medicines in Practice is a series of evidence–based publications specifically designed to support stakeholder medicines optimisation services. The series aims to maximise health gains through the optimum use of medicines, by influencing and changing prescribing behaviour.
Opioids are effective for acute pain and pain at the end of life, but there is little evidence of their effectiveness for long term pain. This document supports primary care teams to review patients receiving regular large quantities of morphine 10mg/5mL oral solution and includes advice on how these patients could be managed.
This publication was updated in September 2022 to include opioid equivalence information to align with the updated Opioids Aware information, and information on safety issues identified with morphine oral solution 10mg/5mL. This update also highlights the availability of the NHSBSA opioid dashboard which can be used to identify patients for review.
Download the full review below to read more.
Monthly Horizon Scanning Report – September 2022
Monthly horizon scanning reports are designed to inform the NHS about new products, significant changes to product licenses, significant new guidance, and decisions that have been made by recognised bodies.
This information is produced for use by NHS healthcare professionals.
Growth Contrast Tool
Overview
The growth contrast tool is intended to help ICBs identify important local effects on prescribing costs. The figures are derived by comparing growth in prescribing costs and items in selected SICBLs with what might have happened if national growth patterns had applied. Comparing actual growth with counterfactuals based on national growth patterns should remove the effect of system-wide changes (e.g. price increases, patent expiries, discontinuations, shortages, implementation of national guidance, etc.) & bring local effects into focus.
Data Period
April 2022 to September 2022
Frequency
Quarterly
Prescribing Update Newsletter – September 2021
Prescribing support newsletters aim to inform readers of work done by the unit and work in progress, to help tailor local work plans and highlight any ‘topical’ issues in prescribing or medicines management.
If you have any suggestions for future topics for the newsletter, then please contact nuth.nyrdtc.rxsupp@nhs.net
This month’s edition covers new labelling requirements for sennosides, changes to the NHS community pharmacy contract, National guidance on blood testing following shortages, and inclisiran in primary care. It also continues a series of spotlight articles on our prescribing data reports; this month takes a look at our prescribing bulletins.
North of England Integrated Care Systems; Overprescribing
This bulletin provides an update on key primary care prescribing trends in the North of England, which relate to ‘Overprescribing’; incorporating ‘Polypharmacy’. It provides a snapshot of overprescribing in the North of England Integrated Care Systems, including the percentage of patients receiving five or more unique analgesic medicines, and those receiving three unique medicines (not licensed for hypertension) with a hypotensive side effect.
A supplementary appendices containing the respective CCG level data is also available to download